Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $16 Million Series A Financing
08:00 EDT 3 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Atterocor, Inc., a company developing an innovative therapy for adrenal
cancer, today announced a $16 million Series A venture capital
financing. Frazier Healthcare and 5AM Ventures led the round and
proceeds from the financing ...
Other Sources for this Article
Pure Communications
Katie Wilson, 910-509-3977
More From BioPortfolio on "Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $16 Million Series A Financing"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
